Publications by authors named "Garance Gutknecht"
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial.
JMIR Res Protoc
October 2023
Article Synopsis
- The study investigates how remote patient monitoring using patient-reported outcomes (PROs) can improve the speed of detecting severe immune-related adverse events (IrAEs) in cancer patients undergoing immune checkpoint inhibitor treatment.
- 198 patients from two Swiss university hospitals are divided into two groups, with one using a digital care model and the other receiving standard care.
- The primary goal is to reduce the time between symptom onset and clinician detection of IrAEs, while secondary goals include evaluating the impact on intervention timing, severity of IrAEs, quality of life, self-efficacy, and overall survival over six months.
Immunocompromised patients (ICPs) have a higher risk of developing severe forms of COVID-19 and experience a higher burden of complications and mortality than the general population. However, recent studies have suggested that the antibody response to SARS-CoV-2 mRNA vaccines could be highly variable among different ICPs. Using a collaborative, monocentric, prospective cohort study, we assessed anti-SARS-CoV-2 spike protein antibody titers following two and three doses of mRNA vaccines in four groups of ICPs (cancer [ = 232]: hematopoietic stem cell transplant [HSCT; = 126] patients; people living with HIV [PLWH; = 131]; and lung transplant [LT; = 39] recipients) treated at Geneva University Hospitals; and healthy individuals ( = 49).
View Article and Find Full Text PDFDevelopment of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
Support Care Cancer
July 2023
Purpose: The use of electronic patient-reported outcome (ePRO) data in routine care has been tied to direct patient benefits such as improved quality of care and symptom control and even overall survival. The modes of action behind such benefits are seldom described in detail. Here, we describe the development of a model of care leveraging ePRO data to monitor and manage symptoms of patients treated with immune checkpoint inhibitors.
View Article and Find Full Text PDFLittle is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines.
View Article and Find Full Text PDF